Thrombotic Microangiopathy (TMA): A potential adverse reaction post Zolgensma (onasemnogene abeparvovec-xioi) therapy for Spinal Muscular Atrophy (SMA) (5483)

202015 citationsJournal Article

Authors

To report a case of TMA in a 6 month-old patient with SMA type 1 after Zolgensma administration.

Good health and well-being

Published in: Neurology

Volume 94, Issue 15_supplement

Field-Weighted Citation Impact: 1.03